|
86 Companies |
|
134 Products |
|
134 Products |
|
85 Mechanisms of Action |
|
5 Trials |
|
1881 News |
|
| «12345678910111213...3738» |
- Trial completion: Assertive Community Treatment With CBT and SST for Schizophrenia (clinicaltrials.gov) - Nov 17, 2016
P=N/A, N=178, Completed, Sponsor: Veterans Medical Research Foundation
Active, not recruiting --> Completed
- Trial completion: Cognitive Remediation and Functional Skills Training in Schizophrenia (clinicaltrials.gov) - Nov 17, 2016
P0, N=75, Completed, Sponsor: National Alliance for Research on Schizophrenia and Depression
Active, not recruiting --> Completed Recruiting --> Completed
- |||| risperidone / Generic mfg., ketamine / Generic mfg.
Trial completion: Schiz_2: Effects of Ketamine and Risperidone on Cognition (clinicaltrials.gov) - Nov 9, 2016
P4, N=87, Completed, Sponsor: University of Manchester
Recruiting --> Completed Not yet recruiting --> Completed
- Trial completion: Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill (clinicaltrials.gov) - Nov 8, 2016
P=N/A, N=176, Completed, Sponsor: University of Washington
Not yet recruiting --> Completed Active, not recruiting --> Completed
- olanzapine / Generic mfg., amisulpride / Generic mfg., clozapine / Generic mfg.
Trial completion, Trial primary completion date: OPTIMISE: Optimization of Treatment and Management of Schizophrenia in Europe (clinicaltrials.gov) - Nov 4, 2016
P4, N=479, Completed, Sponsor: Rene Kahn
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016
- Enrollment closed, Enrollment change: Screening for Childhood-Onset Psychotic Disorders (clinicaltrials.gov) - Nov 3, 2016
P=N/A, N=123, Active, not recruiting, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016 Recruiting --> Active, not recruiting | N=250 --> 123
- Trial completion: Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis (clinicaltrials.gov) - Nov 3, 2016
P=N/A, N=65, Completed, Sponsor: Research Foundation for Mental Hygiene, Inc.
Recruiting --> Active, not recruiting | N=250 --> 123 Active, not recruiting --> Completed
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial primary completion date: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=450, Enrolling by invitation, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Sep 2017
- clozapine / Generic mfg.
Enrollment closed, Trial primary completion date: Vitamin D for Schizophrenia (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=47, Active, not recruiting, Sponsor: Geha Mental Health Center
Trial primary completion date: Dec 2017 --> Sep 2017 Trial primary completion date: Jun 2016 --> Sep 2016 | Recruiting --> Active, not recruiting
- Enrollment closed: Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=546, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2016 --> Sep 2016 | Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial primary completion date: STExFx: Short-term Working Memory and Executive Training (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=40, Recruiting, Sponsor: Queen's University
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jun 2017
- | Trial completion: CHANGE -it is About Life (clinicaltrials.gov) - Oct 27, 2016
P3, N=428, Completed, Sponsor: Mental Health Services in the Capital Region, Denmark
Trial primary completion date: Jun 2016 --> Jun 2017 Active, not recruiting --> Completed
- amisulpride / Generic mfg.
Trial completion, Enrollment change: Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=56, Completed, Sponsor: Birte Glenthoj
Active, not recruiting --> Completed Recruiting --> Completed | N=180 --> 56
- ||||||| aripiprazole / Generic mfg.
Trial completion, Trial primary completion date: A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia (clinicaltrials.gov) - Oct 26, 2016
P2/3, N=106, Completed, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Recruiting --> Completed | N=180 --> 56 Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Nov 2014
- valacyclovir / Generic mfg.
Trial completion, Trial primary completion date: Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia (clinicaltrials.gov) - Oct 26, 2016
P4, N=134, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Nov 2014 Enrolling by invitation --> Completed | Trial primary completion date: May 2016 --> Sep 2016
- sodium valproate / Generic mfg.
Enrollment closed, Trial primary completion date: Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia (clinicaltrials.gov) - Oct 26, 2016
P4, N=109, Active, not recruiting, Sponsor: University of Pittsburgh
Enrolling by invitation --> Completed | Trial primary completion date: May 2016 --> Sep 2016 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Oct 2017
- ||||||| aripiprazole / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia (clinicaltrials.gov) - Oct 26, 2016
P3, N=68, Completed, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Oct 2017 Active, not recruiting --> Completed | N=30 --> 68 | Trial primary completion date: Apr 2016 --> Nov 2015
- Trial completion: OPUSII: Extended Specialized Assertive Intervention for First Episode Psychosis (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=400, Completed, Sponsor: University of Copenhagen
Active, not recruiting --> Completed | N=30 --> 68 | Trial primary completion date: Apr 2016 --> Nov 2015 Active, not recruiting --> Completed
- memantine ER / Generic mfg., galantamine extended release / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia (clinicaltrials.gov) - Oct 12, 2016
P2, N=3, Terminated, Sponsor: Sheppard Pratt Health System
Active, not recruiting --> Completed N=10 --> 3 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Jul 2016; Funding no longer available and PI no longer working at the institution
- ||||||| Trial completion: Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia (clinicaltrials.gov) - Oct 6, 2016
P3, N=209, Completed, Sponsor: GlaxoSmithKline
N=10 --> 3 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Jul 2016; Funding no longer available and PI no longer working at the institution No longer recruiting --> Completed
- ||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion, Trial primary completion date: ZENITH: Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia (clinicaltrials.gov) - Oct 4, 2016
P3, N=1044, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
No longer recruiting --> Completed Enrolling by invitation --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016
- Arvisol (cannabidiol) / Echo Pharma
Preclinical, Trial primary completion date: CBD-IS: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (clinicaltrials.gov) - Oct 3, 2016
P1, N=74, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
Enrolling by invitation --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016 Trial primary completion date: Oct 2016 --> Feb 2017
- | Trial completion: TARA: Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia (clinicaltrials.gov) - Sep 30, 2016
P=N/A, N=16, Completed, Sponsor: Posit Science Corporation
Trial primary completion date: Oct 2016 --> Feb 2017 Recruiting --> Completed
- Trial primary completion date: Understanding How Cognitive Remediation Works (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=244, Recruiting, Sponsor: Boston University
Recruiting --> Completed Trial primary completion date: Jan 2017 --> Nov 2018
- bupropion / Generic mfg.
Enrollment change: Smoking Relapse Prevention in Schizophrenia (clinicaltrials.gov) - Sep 27, 2016
P4, N=25, Completed, Sponsor: North Suffolk Mental Health Association
Trial primary completion date: Jan 2017 --> Nov 2018 N=300 --> 25
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Sep 26, 2016
P1, N=5, Suspended, Sponsor: Monash University
N=300 --> 25 Trial primary completion date: Jul 2016 --> Jul 2018
- Enrollment open: SPA: A System for Preference Assessment in Mental Health (clinicaltrials.gov) - Sep 20, 2016
P=N/A, N=90, Recruiting, Sponsor: University of California, Los Angeles
Trial primary completion date: Jul 2016 --> Jul 2018 Not yet recruiting --> Recruiting
- Trial completion, Trial primary completion date, HEOR: PULSAR: Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia (clinicaltrials.gov) - Sep 16, 2016
P2, N=70, Completed, Sponsor: Medical Universtity of Lodz
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Feb 2015
- Trial primary completion date: Feeling of Being in Control of One's Own Action (clinicaltrials.gov) - Sep 16, 2016
P=N/A, N=370, Recruiting, Sponsor: University Hospital, Strasbourg, France
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Feb 2015 Trial primary completion date: Dec 2018 --> Dec 2017
- Trial primary completion date: REACH: Researching the Effectiveness of Acceptance-Based Coping During Hospitalization (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=60, Recruiting, Sponsor: Butler Hospital
Trial primary completion date: Dec 2018 --> Dec 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- |||| Perseris (risperidone sustained-release 1-month depot) / Indivior, Reckitt Benckiser, HLS Therap
Clinical: Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia (clinicaltrials.gov) - Sep 12, 2016
P3, N=500, Active, not recruiting, Sponsor: Indivior Inc.
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Mar 2018 --> Oct 2016
- Trial completion, Enrollment change: Online Family Support and Education for Schizophrenia (clinicaltrials.gov) - Sep 9, 2016
P=N/A, N=42, Completed, Sponsor: University of California, Los Angeles
Trial primary completion date: Mar 2018 --> Oct 2016 Active, not recruiting --> Completed | N=72 --> 42
- Trial primary completion date: Exercise and Cognitive Training (clinicaltrials.gov) - Sep 9, 2016
P0, N=30, Recruiting, Sponsor: Boston University
Active, not recruiting --> Completed | N=72 --> 42 Trial primary completion date: Jun 2016 --> Jun 2017
- Enrollment change, Trial termination, Trial primary completion date, HEOR, Adherence: MAPP: Milestones of Adjustment Post-Psychosis (clinicaltrials.gov) - Sep 8, 2016
P3, N=110, Terminated, Sponsor: Yale University
Trial primary completion date: Jun 2016 --> Jun 2017 N=60 --> 110 | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Jan 2013
- Trial primary completion date: DCS: Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine (clinicaltrials.gov) - Sep 7, 2016
P0, N=2, Enrolling by invitation, Sponsor: Mclean Hospital
N=60 --> 110 | Recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Jan 2013 Trial primary completion date: Sep 2016 --> Feb 2017
- Trial completion, Enrollment change: Clinical Monitoring to Facilitate Continuous Care for Substance Abusing Clients (clinicaltrials.gov) - Sep 2, 2016
P=N/A, N=139, Completed, Sponsor: Treatment Research Institute
Trial primary completion date: Sep 2016 --> Feb 2017 N=175 --> 139 | Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) (clinicaltrials.gov) - Sep 1, 2016
P=N/A, N=332, Completed, Sponsor: Jordi Gol i Gurina Foundation
N=175 --> 139 | Active, not recruiting --> Completed Recruiting --> Completed | N=480 --> 332 | Trial primary completion date: Jun 2014 --> Mar 2015
- Enrollment change, Trial termination, Trial primary completion date: tDCS & Auditory Hallucinations in Schizophrenia (clinicaltrials.gov) - Aug 31, 2016
P=N/A, N=3, Terminated, Sponsor: Herzog Hospital
Recruiting --> Completed | N=480 --> 332 | Trial primary completion date: Jun 2014 --> Mar 2015 N=30 --> 3 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Aug 2016; Lack of participants that fit inclusion criteria
- ||||||| Trial completion: Clinical Study Of Schizophrenia in Both Men and Women (clinicaltrials.gov) - Aug 30, 2016
P3, N=176, Completed, Sponsor: GlaxoSmithKline
N=30 --> 3 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Aug 2016; Lack of participants that fit inclusion criteria No longer recruiting --> Completed
- Enrollment closed: Integrated Metacognitive Therapy in First Episode Psychosis (clinicaltrials.gov) - Aug 30, 2016
P=N/A, N=20, Active, not recruiting, Sponsor: Indiana University
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Chantix (varenicline) / Pfizer
Trial completion, Enrollment change: Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia (clinicaltrials.gov) - Aug 26, 2016
P2, N=58, Completed, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=40 --> 58
- Enrollment change, Trial termination, Trial primary completion date: Pain and Schizophrenia (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=83, Terminated, Sponsor: University Hospital, Strasbourg, France
Active, not recruiting --> Completed | N=40 --> 58 N=107 --> 83 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Jan 2015; recruitment difficulties
- Enrollment change, Trial termination: Internal Monitoring of Eye Movement in Schizophrenia (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=2, Terminated, Sponsor: National Eye Institute (NEI)
N=107 --> 83 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Jan 2015; recruitment difficulties N=25 --> 2 | Recruiting --> Terminated
- Trial completion: Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in Schizophrenia (clinicaltrials.gov) - Aug 16, 2016
P=N/A, N=30, Completed, Sponsor: Charite University, Berlin, Germany
N=25 --> 2 | Recruiting --> Terminated Recruiting --> Completed
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion, Trial primary completion date, Monotherapy: Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity (clinicaltrials.gov) - Aug 12, 2016
P3, N=38, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016
- Trial completion, Enrollment change: AHCM: Addiction Housing Case Management for Homeless Veterans (clinicaltrials.gov) - Aug 11, 2016
P=N/A, N=181, Completed, Sponsor: VA Office of Research and Development
Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016 Active, not recruiting --> Completed | N=400 --> 181
- clonidine / Generic mfg., dronabinol oral / Generic mfg.
Trial primary completion date: Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia (clinicaltrials.gov) - Aug 10, 2016
P2/3, N=18, Recruiting, Sponsor: Mclean Hospital
Active, not recruiting --> Completed | N=400 --> 181 Trial primary completion date: Mar 2016 --> Mar 2017
- Trial primary completion date: Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study (clinicaltrials.gov) - Aug 9, 2016
P=N/A, N=91, Enrolling by invitation, Sponsor: Sykehuset Innlandet HF
Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: May 2016 --> Sep 2016
- mirtazapine / Generic mfg.
Trial completion, Trial primary completion date: RECOVERY2: Evaluation of Mirtazapine and Folic Acid for Schizophrenia: (clinicaltrials.gov) - Aug 3, 2016
P4, N=333, Completed, Sponsor: Capital Medical University
Trial primary completion date: May 2016 --> Sep 2016 Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Dec 2012
- ||| Nuplazid (pimavanserin) / Acadia Pharma
Enrollment closed, Trial primary completion date: A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis (clinicaltrials.gov) - Aug 3, 2016
P2, N=181, Active, not recruiting, Sponsor: ACADIA Pharmaceuticals Inc.
Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Dec 2012 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016